MedTrace Logo

A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19

NCT04379492 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-05-16

No results posted yet for this study

Summary

This study is being done to see if hydroxychloroquine is an effective treatment for COVID-19.

Conditions

Interventions

DRUG

Hydroxychloroquine

Participants will receive hydroxycholoroquine (200-mg tablets) 2 tablets orally q12h for 2 doses on day 1 (load), followed by 1 tablet orally q12h for days 2-5.

OTHER

Placebo

Participants will receive masked placebo given as 2 tablets orally q12h for 2 doses on day 1, followed by 1 tablet orally q12h for days 2-5.

Sponsors & Collaborators

Principal Investigators

  • Genovefa Papanicolaou, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-05
Primary Completion
2020-09-25
Completion
2020-09-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04379492 on ClinicalTrials.gov